Guidelines for reporting data to the 2016 survey of cellular therapy and regenerative medicine in Europe and neighboring Eurasian countries

Please report the **total number of patients** receiving cell or engineered tissue therapies in 2016 and **NOT the number of procedures** according to the rules below. Please complete one form per team.

**If you did not perform such therapies in 2016**, but have in the past or plan to in the future, please mark this at the bottom of the survey and include a contact person with their contact details and affiliation.

The definition of novel cell therapies or engineered tissues is any clinical treatment based on living cells excluding:

- DLIs – Donor Lymphocyte Infusions
- Non-manipulated hematopoietic cells for hematological reconstitution (these treatments should be reported using the companion EBMT activity survey)

**Totals:** In order to use your data, please complete each of the sections A, B, C and D. The **total number of patients recorded in each section should be the same**, i.e.: total numbers in Part A (sum of all cell types and source) should equal the total numbers in Part B1, B2, B3, B4, B5 and part C, as well as the total numbers in Part D1, D2, D3.

**Part A: Cell type and source**
Report the total number of patients according to disease indication, donor type, cell type and cell source. **BM** = bone marrow; **CB** = cord blood; **PB** = peripheral blood; **Plac** = placenta, **Fat** = adipose tissue. If you used more than one cell type please provide an explanatory comment in the designated field at the bottom of the page.

**Part B: Processing**
Report the total number of patients according to disease indication and processing protocol. Each patient should be entered in parts B1, B2, B3, B4, and B5.
- **Expanded** = including any *in-vitro* manipulation
- **Transduced** = after genetic modification
- **Sorted** = after MACS- or FACS-based separation
- **Automated** = when at least one step of cell isolation or culture is performed with an automated device, i.e. a specifically designed instrument beyond a centrifuge or sorter.
- **In House** = if the cells or construct were processed in the own facility
- **Out Sourced** = if cells were given to an external facility or company for processing
  Please specify the contracted facility at the bottom of the page.

**Part C: Delivery mode**
Report the total number of patients according to disease indication and the delivery mode.
- **I.V. / I.A.** = intravenous or intra-arterial cell delivery
- **Intra-organ injections, suspension** = cell delivery in a fluid material
- **Gel** = cell delivery in a gel
- **Membrane/Scaffold** = cell delivery after loading on a solid carrier

**Part D: Clinical Procedure**
Please enter the total number of patients according to indication who were treated as
- part of a **clinical trial**
- a **case study**
- part of **routine therapy**

Add any additional or clarifying information in the comments field (e.g., which indication, cell type or source was used if classified under ‘Other’)

Indicate your **affiliation** by entering your EBMT CIC number or ticking one of the boxes (ICRS, IFATS, ISCT, TERMIS) and enter your **name and team plus address** in the panel on page 2 of the survey sheet. These details will be reported in the appendix to the survey analysis.

**If you need help with submitting your data please contact Max Gay directly.**
Please send the completed activity survey either by post or email.

By Post to Max Gay, Lab 405, Tissue Engineering, University Hospital Basel, Hebelstrasse 20, CH 4031, Basel, Switzerland.
By E mail to: max.g@usb.ch  
telephone: +41 61 328 7375
## Cellular Therapy and Regenerative Medicine Survey 2016

**Patients treated in 2016**

<table>
<thead>
<tr>
<th>Donor Type</th>
<th>Hematopoietic cells</th>
<th>Mesenchymal stromal cells</th>
<th>Chondrocytes</th>
<th>Keratinocytes</th>
<th>Ovarian primordial follicles</th>
<th>Endothelial cells</th>
<th>Muscle cells</th>
<th>Other</th>
<th>Please specify</th>
<th>B1</th>
<th>B2</th>
<th>B3</th>
<th>B4</th>
<th>B5</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM</td>
<td>CS</td>
<td>PB</td>
<td>Other</td>
<td>BM</td>
<td>Plac</td>
<td>CS</td>
<td>Fat</td>
<td>Other</td>
<td>BM</td>
<td>CS</td>
<td>CS</td>
<td>CS</td>
<td>CS</td>
<td>CS</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial ischemia</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bypass graft</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valve replacement</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decubitus + leg ulcers</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Musculoskeletal/Rheumatological**

<table>
<thead>
<tr>
<th>Donor Type</th>
<th>Hematopoietic cells</th>
<th>Mesenchymal stromal cells</th>
<th>Chondrocytes</th>
<th>Keratinocytes</th>
<th>Ovarian primordial follicles</th>
<th>Endothelial cells</th>
<th>Muscle cells</th>
<th>Other</th>
<th>Please specify</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone repair (maxillofacial)</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone repair (orthopaedics)</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteogenesis imperfecta</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cartilage repair (maxillofacial)</td>
<td>Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Hematology/Oncology**

<table>
<thead>
<tr>
<th>Donor Type</th>
<th>Hematopoietic cells</th>
<th>Mesenchymal stromal cells</th>
<th>Chondrocytes</th>
<th>Keratinocytes</th>
<th>Ovarian primordial follicles</th>
<th>Endothelial cells</th>
<th>Muscle cells</th>
<th>Other</th>
<th>Please specify</th>
</tr>
</thead>
</table>

**Hematological malignancies**

<table>
<thead>
<tr>
<th>Donor Type</th>
<th>Hematopoietic cells</th>
<th>Mesenchymal stromal cells</th>
<th>Chondrocytes</th>
<th>Keratinocytes</th>
<th>Ovarian primordial follicles</th>
<th>Endothelial cells</th>
<th>Muscle cells</th>
<th>Other</th>
<th>Please specify</th>
</tr>
</thead>
</table>

**TOTALS**

<p>| | | | | | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Please specify Other Indications:**

- Please specify Other cell sources or if multiple cell sources were used in combination.
- Patients with Peripheral artery disease were treated in a combination of Muscle cells and MSCs from CB.
- Please specify the facility you found sourced the processing to:

**Tick relevant organisation**

- EBMT
- CIC No: 
- ICN:
- IFATS:
- ISCT:
- TERMIS:

**I did not perform cell therapies in 2016 but I will do so in the future**

**Year of last or planned cell therapy**

Send to: Max G, Tissue Engineering, ZUF, Hebelstrasse 20

University Hospital, CH-4031 Basel, Switzerland

E-mail: max.g@usb.ch